Total
0
Shares
McPhersons (ASX:MCP) - Resigned CEO & Managing Director, Laurie McAllister
Resigned CEO & Managing Director, Laurie McAllister
Source: The CEO Magazine
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Laurie McAllister has resigned as CEO and Managing Director of McPherson’s (MCP), effective December 9
  • Laurie has led the health and wellness company over the past four years and MCP says he leaves the company in a strong position for future growth
  • One of his highlights is the successful acquisition of Global Therapeutics in NSW
  • In the interim, Non-Executive Director Grant Peck will replace Laurie to aid in the transition to a more permanent holder
  • McPherson’s will now begin the steps to appoint a more permanent CEO and Managing Director and will provide further announcements in due course
  • Company shares are down 6.8 per cent and are trading at $1.17

Laurie McAllister has resigned as CEO and Managing Director of McPherson’s (MCP), effective December 9.

Laurie has led the health and wellness company over the past four years and MCP says he leaves the company in a strong position for future growth.

One of his highlights is the successful acquisition of Global Therapeutics in Byron Bay, NSW.

Before joining McPherson’s, Laurie worked at Coca-Cola for 23 years, where he had a stint as the Chief Commercial & Marketing Officer for Japan.

Laurie will remain available for a short period of time to assist McPherson’s executive team if required.

In the interim, Non-Executive Director Grant Peck will replace Laurie, effective December 10. This will provide continuity and aid in the transition to a more permanent holder.

Grant has been a Non-Executive Director since December 2017 and is also a member and Chairman of McPherson’s Audit, Risk Management and Compliance Committee.

McPherson’s will now begin the steps to appoint a more permanent CEO and Managing Director and will provide further announcements in due course.

Company shares are down 6.8 per cent and are trading at $1.17 at 2:10 pm AEDT.

MCP by the numbers
More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.